Immuneering Corporation — Q3 2023 Form 10-Q
Reporting period: Three and nine months ended September 30, 2023. Immuneering is a clinical-stage oncology company developing therapies targeting the MAPK pathway. Its lead candidate, IMM-1-104, was in a Phase 1/2a trial for advanced RAS-mutant solid tumors; IMM-6-415 was in IND-enabling studies. The company had no approved products and no product sales.
Financial results and liquidity
| Metric | Q3 2023 | Q3 2022 | Nine months 2023 | Nine months 2022 |
|---|---|---|---|---|
| Revenue | $0 | $38,380 | $0 | $316,497 |
| Research and development | $10.05 million | $9.36 million | $29.71 million | $26.40 million |
| General and administrative | $3.87 million | $3.84 million | $12.38 million | $11.50 million |
| Operating loss | $13.93 million | $13.19 million | $42.11 million | $37.76 million |
| Net loss | $12.60 million | $12.84 million | $38.39 million | $37.27 million |
| Basic and diluted loss per share | $0.43 | $0.49 | $1.36 | $1.41 |
Gross margin is not meaningful for 2023 because the company reported no revenue or cost of revenue. Q3 net loss narrowed 1.9% year over year, while nine-month net loss increased 3.0%. Operating expenses rose 5.4% in Q3 and 11.1% over nine months. Higher R&D spending, particularly on IMM-1-104, was a principal driver; increased interest income partly offset operating losses.
At September 30, 2023, cash and cash equivalents were $68.0 million and current marketable securities were $29.2 million, totaling approximately $97.2 million. Total current assets were $100.6 million and current liabilities were $5.6 million. Total liabilities were $9.9 million, primarily lease liabilities; the filing reports no debt borrowing. Accumulated deficit was $148.2 million.
For the first nine months, operating activities used $37.2 million of cash, investing activities provided $4.2 million, and financing activities provided $28.4 million, including $28.2 million net proceeds from an April follow-on stock offering. Cash and cash equivalents declined $4.6 million from year-end 2022. The follow-on offering issued 2,727,273 shares at $11 per share.
Developments, outlook, and risks
- IMM-1-104 R&D expense was $2.2 million in Q3, up 65% year over year, and $5.3 million for the nine months, up 98%. The company reported that the dose-escalation committee observed tolerability through 320 mg once daily with no dose-limiting toxicities, and that Phase 1b dose evaluation had begun. These are early-stage findings, not evidence of efficacy.
- Management estimated existing cash, cash equivalents, and marketable securities would fund operations into 2025, based on assumptions that may prove incorrect. The financial statements state management found no substantial doubt about continuing as a going concern for at least 12 months from issuance. The company expects continued losses and rising development and operating expenses and may need additional capital.
- As stated in the filing, management expected to provide a projected Phase 2 dose recommendation and additional IMM-1-104 safety data, and begin Phase 2a dosing in early 2024; initial Phase 2a data were expected in 2024. It also planned to submit an IMM-6-415 IND in Q4 2023. These are forward-looking plans, not reported outcomes.
- After quarter-end, the company reported additional preclinical combination data in October and an expanded IMM-1-104 trial plan in November, including planned combination and monotherapy arms. The filing does not establish clinical benefit from these preclinical findings.
- After quarter-end, Chief Medical Officer Scott Barrett’s planned departure effective November 30, 2023 was disclosed; the Chief Scientific Officer was to lead clinical activities interim while the company searched for a replacement.
- Key risks include clinical and regulatory uncertainty, patient enrollment and trial delays, safety or efficacy failures, reliance on third-party manufacturers and research organizations, intellectual-property protection, and the need for further financing. The company reported no material legal proceedings and no material off-balance-sheet arrangements.
Investor facts to verify
- Trial progress, enrollment, safety, and eventual efficacy data for IMM-1-104; distinguish interim findings from final results.
- Whether the planned IMM-6-415 IND submission and IMM-1-104 dose and Phase 2 milestones occurred on the stated timelines.
- Cash burn, investment balances, and the assumptions behind management’s runway estimate into 2025; assess potential financing and dilution needs.
- Execution and resourcing of the expanded clinical plan, including the Chief Medical Officer transition and third-party supply arrangements.
- Patent prosecution and the scope of protection: the filing reports no issued patents related to product candidates as of September 30, 2023.